Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Committee Legislative Actions topic
No spam. Unsubscribe anytime.
Committee advances prostate‑screening coverage bill and clears insulin‑assistance, data‑privacy fixes
Summary
The Assembly Health Committee amended and released three bills: A‑1841 (expanded prostate‑screening coverage for high‑risk men), A‑4015/S‑2886 (pharmacy insulin assistance information), and A‑5017 (narrow data‑privacy exemptions for certain regulatory organizations). A‑1841 prompted the most debate, including concerns about USPSTF guidance and fiscal impact.
The Assembly Health Committee advanced three separate bills after expert testimony and stakeholder remarks.
A‑1841 — Prostate cancer screening for high‑risk men: The committee considered amendments to A‑1841 that tie annual prostate screening to the "latest nationally recognized clinical practice guidelines" and remove a statutory definition of screening. Quentin Law of the American Cancer Society Cancer Action Network testified the change would remove cost barriers for high‑risk men and could improve early detection; he cited higher prostate cancer incidence and mortality among Black men. Ward Sanders of the New Jersey Association of Health Plans supported evidence‑based screening but cautioned that the U.S. Preventive Services Task Force assigns prostate screening a "C" rating and that mandates can lead to follow‑on costs from diagnostic workups and potential overtreatment. After discussion and a point of order about referral to the mandated Health Benefits Advisory Committee, the committee moved, seconded and recorded the result: the bill was amended and released for further consideration.
A‑4015/S‑2886 — Insulin manufacturer assistance information at pharmacies: The committee adopted amendments to require pharmacies to conspicuously display information about insulin manufacturer assistance programs on their websites, to provide pamphlets on request, and to have the Department of Health draft the required content; the bills were amended and released with support from pharmacy groups.
A‑5017 — Data‑privacy exemptions for certain regulatory organizations: The committee considered a bill to exempt certain entities that support insurance or securities regulation from aspects of the state data privacy law so they can continue regulatory and fraud‑fighting activities. Testimony from industry and enforcement groups (including FINRA and the National Insurance Crime Bureau) described operational constraints the current privacy law imposes on investigations. The committee amended and released the bill.
What to watch: A‑1841 generated the most substantive debate about evidence and scope, with stakeholders asking for clarity about which populations would be covered and what the fiscal impact would be. The committee flagged OLS guidance that the bill could proceed without a further Health Benefits Advisory Committee finding but members asked for written confirmation.
The committee adjourned after taking the three votes.
